Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (2): 254-260. doi: 10.19723/j.issn.1671-167X.2020.02.010
Previous Articles Next Articles
Guo-hong SONG1,Hui-ping LI1,△(),Li-jun DI1,Ying YAN1,Han-fang JIANG1,Ling XU2,Dong-gui WAN3,Ying LI4,Mo-pei WANG5,Yu XIAO5,Ru-yan ZHANG1,Ran RAN1,Huan WANG1
CLC Number:
[1] | Slamon DJ, Clark GM, Wong SG , et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987,235(4785):177-182. |
[2] | Xu B, Hu X, Zheng H , et al. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo) adjuvant trastuzumab: A prospective multicenter study[J]. Oncotarget, 2016,7(31):50643-50655. |
[3] | Cobleigh M, Yardley D, Brufsky AM , et al. Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from SystHERs[J]. Clin Cancer Res, 2020,26(5):1105-1113. |
[4] | Ma F, Li Q, Chen S , et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017,35(27):3105-3112. |
[5] | Li Q, Guan X, Chen S , et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase Ⅰ clinical trial[J]. Clin Cancer Res, 2019,25(17):5212-5220. |
[6] | Ma F, Ouyang Q, Li W , et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study[J]. J Clin Oncol, 2019,37(29):2610-2619. |
[7] | Jiang ZF, Yan M, Hu XC , et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase Ⅲ study[J]. J Clin Oncol, 2019,37(15 suppl):1001. |
[8] | Wong H, Leung R, Kwong A , et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 + metastatic breast cancer [J]. Oncologist, 2011,16(11):1535-1546. |
[9] | Dawood S, Broglio K, Buzdar AU , et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review[J]. J Clin Oncol, 2010,28(1):92-98. |
[10] | Slamon DJ, Leyland-Jones B, Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001,344(11):783-792. |
[11] | Burstein HJ, Keshaviah A, Baron AD , et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study[J]. Cancer, 2007,110(5):965-972. |
[12] | Robert N, Leyland-Jones B, Asmar L , et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpres-sing metastatic breast cancer[J]. J Clin Oncol, 2006,24(18):2786-2792. |
[13] | Geyer CE, Forster J, Lindquist D , et al. Lapatinib plus capeci-tabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743. |
[14] | Cameron D, Casey M, Oliva C , et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase Ⅲ randomized trial[J]. Oncologist, 2010,15(9):924-934. |
[15] | Xu BH, Jiang ZF, Chua D , et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients[J]. Chin J Cancer, 2011,30(5):327-335. |
[16] | Baselga J, Cortés J, Kim SB , Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012,366(2):109-119. |
[17] | Verma S, Miles D, Gianni L , et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012,367(19):1783-1791. |
[18] | Leyland-Jones B . Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases[J]. J Clin Oncol, 2009,27(31):5278-5286. |
[19] | Ramakrishna N, Temin S, Chandarlapaty S , et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014,32(19):2100-2108. |
[20] | Ramakrishna N, Temin S, Chandarlapaty S , et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update[J]. J Clin Oncol, 2018,36(27):2804-2807. |
[21] | Bachelot T, Romieu G, Campone M , et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study[J]. Lancet Oncol, 2013,14(1):64-71. |
[22] | Montemurro F, Ellis P, Delaloge S, et al. Safety and efficacy of trastuzumab emtansine(>T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study[J].Cancer Res, 2017, 77(4 Suppl):P1-12-10. |
[1] | Ying TANG, Yongbo ZHANG, Danhong WU, Yanhong LIN, Fenghua LAN. Detection of pathogenic gene mutations in thirteen cases of congenital bilateral absence of vas deferens infertility patients [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 763-774. |
[2] | Jian-xun MA,You-chen XIA,Bi LI,Hong-mei ZHAO,Yu-tao LEI,Xi BU. Choice of immediate breast reconstructive methods after modified radical mastectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 612-618. |
[3] | Yun-jing ZHANG,Li-ying QIAO,Meng QI,Ying YAN,Wei-wei KANG,Guo-zhen LIU,Ming-yuan WANG,Yun-feng XI,Sheng-feng WANG. Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 471-479. |
[4] | Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253. |
[5] | Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078. |
[6] | Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862. |
[7] | Xiao-jing CHENG,Dong JIANG,Lian-hai ZHANG,Jiang-hua WANG,Ya-zhen LI,Jia-hui ZHAI,Bao-qi YAN,Lu-lu ZHANG,Xing-wang XIE,Zi-yu LI,Jia-fu JI. Preclinical study of T cell receptor specifically reactive with KRAS G12V mutation in the treatment of malignant tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 884-895. |
[8] | Zhi-qing LI,Bing YU,Ze-yu CAI,Ying-bao WANG,Xu ZHANG,Biao ZHOU,Xiao-hong FANG,Fang YU,Yi FU,Jin-peng SUN,Wei LI,Wei KONG. Naringenin inhibits thoracic aortic aneurysm formation in mice with Marfan syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 896-906. |
[9] | Tian-yu CAI,Zhen-peng ZHU,Chun-ru XU,Xing JI,Tong-de LV,Zhen-ke GUO,Jian LIN. Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 628-635. |
[10] | GU Yang-chun,LIU Ying,XIE Chao,CAO Bao-shan. Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 369-375. |
[11] | TIAN Jia-yi,ZHANG Xia,CHENG Gong,LIU Qing-hong,WANG Shi-yang,HE Jing. Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1083-1087. |
[12] | LIAO Xu-he,WANG Rong-fu,LIU Meng,CHEN Xue-qi,XIONG Yan,NONG Lin,YIN Lei,ZHANG Bing-ye,DU Yu-jing. Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 246-254. |
[13] | Xiao-peng ZHANG,Wei-yu ZHANG,Fei HUO,Hao HU,Qi WANG,Ke-xin XU. Outcome of surgical management and pathogenesis of female primary bladder neck obstruction [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1052-1055. |
[14] | Xue-jun LIANG,Li-ying GONG,Fei ZHOU,De-min ZHOU,Jing-jing ZHU. Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 797-804. |
[15] | Xin-yun YAO,Xiao-min GAO,Xiao-ying ZOU,Lin YUE. Role of endocytosis in cell surface CXC chemokine receptor 4 expression of stem cells from apical papilla [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 893-899. |
|